Ketanserin versus nifedipine in the treatment of essential hypertension in patients over 50 years old: an international multicenter study
- PMID: 2446056
Ketanserin versus nifedipine in the treatment of essential hypertension in patients over 50 years old: an international multicenter study
Abstract
The serotonergic antagonist ketanserin (K) was compared to nifedipine (N) in a five-center international study on hypertensive patients over the age of 50 years. After a 4-week placebo run-in period, patients were randomly assigned to receive for 3 months either ketanserin (40 mg b.i.d. after 2 weeks of 20 mg b.i.d.) or nifedipine (20 mg N retard b.i.d.). After 1 month, monotherapy patients whose blood pressure was not sufficiently reduced received a diuretic in combination therapy. At the end of the active treatment period, patients who had remained on monotherapy received placebo until hypertension returned or for a maximum of 2 months. One hundred and seventeen patients were entered in the study, 58 on K and 59 on N. More patients switched to combination with a diuretic in the K group (14 patients) than in the N group (6 patients). The overall reduction in blood pressure was similar for K and N. Total response rate was high (96%) for the two drugs. Blood pressure was reduced both at peak and trough drug levels. No orthostatic reactions were observed, and no rebound hypertension occurred at discontinuation of therapy. Ketanserin monotherapy slightly decreased heart rate (-1 beats/min). whereas N produced a significant increase (+6 beats/min). Body weight significantly increased with K (+1.1 kg) and was unchanged with N. More patients complained of adverse reactions during N monotherapy (47%) than during K monotherapy (34%). Flushing and leg edema were more frequent with N.
Similar articles
-
Evaluation of a new antihypertensive agent ketanserin versus methyldopa in the treatment of essential hypertension in older patients: an international multicenter trial.J Cardiovasc Pharmacol. 1987;10 Suppl 3:S113-8. J Cardiovasc Pharmacol. 1987. PMID: 2446057 Clinical Trial.
-
Ketanserin compared to nifedipine and methyldopa in patients aged above 50 years: two international multicentre studies. For the International Study Group.J Hypertens Suppl. 1986 Dec;4(6):S115-8. J Hypertens Suppl. 1986. PMID: 3302148 Clinical Trial.
-
Ketanserin in mild to moderate hypertension in the elderly: a double-blind study versus methyldopa.Clin Ther. 1989 May-Jun;11(3):363-72. Clin Ther. 1989. PMID: 2663164 Clinical Trial.
-
[Cardiac interactions between ketanserin and the calcium antagonist nifedipine].Schweiz Med Wochenschr. 1992 Nov 7;122(45):1723-7. Schweiz Med Wochenschr. 1992. PMID: 1279788 German.
-
Clinical aspects during therapy with the serotonin antagonist ketanserin.Clin Physiol Biochem. 1990;8 Suppl 3:64-80. Clin Physiol Biochem. 1990. PMID: 1983424 Review.
Cited by
-
Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.Drugs. 1990 Dec;40(6):903-49. doi: 10.2165/00003495-199040060-00010. Drugs. 1990. PMID: 2079001 Review.
-
Comparison of ketanserin and enalapril in the treatment of mild-to-moderate essential hypertension.Cardiovasc Drugs Ther. 1990 Jan;4 Suppl 1:123-6. doi: 10.1007/BF00053443. Cardiovasc Drugs Ther. 1990. PMID: 2285642 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical